Implantable Cardioverter-Defibrillator Therapy in Brugada Syndrome
JACC: Clinical Electrophysiology · 2025
DOI: 10.1016/j.jacep.2025.01.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2025. Verfasst von Cinzia Monaco und 26 weiteren Autor:innen. Beteiligte Einrichtung: Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks, Guard-Heart, Vrije Univers…. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Brugada Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Brugada syndrome (BrS) continues to pose clinical challenges, despite 3 decades of dedicated research and therapeutic advancements. The pivotal role of implantable cardioverter-defibrillator (ICD) therapy in safeguarding high-risk BrS patients from sudden cardiac death due to ventricular arrhythmias is undeniable. However, the debate on risk stratification and the use of ICDs for primary prevention remains ongoing. OBJECTIVES: This study aimed to evaluate the clinical features, management, and long-term outcomes of ICD therapy in patients with Brugada syndrome. METHODS: BrS-diagnosed patients were prospectively enrolled. Inclusion criteria were: 1) a Brugada type 1 electrocardiogram pattern, either spontaneous or drug induced; 2) ICD implantation; and 3) consistent follow-up. Risk stratification was based on prior arrhythmic events, and the multiparametric Brussel risk score was used from 2017. High-risk patients underwent video-thoracoscopic epicardial ablation starting in 2016. ICD implantation strategies evolved over time, guided by patients' clinical and demographic characteristics. RESULTS: A total of 306 consecutive Brugada patients (186 male [61%]; mean age 41 ± 17 years; range: 1-82 years) received ICDs at our institution from 1992 to 2022. ICDs were implanted for secondary prevention in 16% of patients. Over the 3 decades, the proportions of secondary prevention implants and asymptomatic patients remained stable, while risk factors fluctuated in the first two decades before stabilizing. During long-term follow-up (median 103 months [63-147 months]), 14% of patients experienced at least 1 sustained ventricular arrhythmia (VA) (1.59 per 100 person-years), 15% had at least 1 inappropriate ICD shock-unaffected by the presence of single or dual leads-and 27% required device revision and/or lead replacement. Patients with secondary prevention ICDs had a higher incidence of both ventricular and supraventricular arrhythmias compared to those with primary prevention ICDs. Loss-of-function mutations and prior nonsustained VAs were associated with sustained VAs. Among high-risk patients, those who underwent epicardial ablation experienced significantly fewer ventricular events. The overall mortality rate was 5.88%, with 22.2% of deaths attributed to cardiac causes. CONCLUSIONS: This 30-year study highlights ICD therapy's critical role in preventing fatal arrhythmias in Brugada syndrome, but also reveals frequent device-related complications, especially in younger patients. Thoracoscopic epicardial ablation significantly reduced VA in high-risk patients, offering a promising adjunctive therapy. These findings emphasize the need for individualized treatment strategies to balance the benefits of ICDs with their risks, and underscore the potential of ablation to improve long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks, Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.
- Cardiac Surgery Department, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.
- Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks, Guard-Heart, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium. Ele…
Zitieren
APA
Monaco, C., Cespon-Fernandez, M., Pannone, L., Del Monte, A., Della Rocca, D., Gauthey, A., Mouram, S., Marcon, L., Vetta, G., Audiat, C., Doundoulakis, I., Bisignani, A., Miraglia, V., Pappaert, G., Eltsov, I., Bala, G., Sorgente, A., Overeinder, I., Almorad, A., …, & de Asmundis, C. (2025). Implantable Cardioverter-Defibrillator Therapy in Brugada Syndrome. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2025.01.013
Vancouver
Monaco C, Cespon-Fernandez M, Pannone L, Del Monte A, Della Rocca D, Gauthey A, et al. Implantable Cardioverter-Defibrillator Therapy in Brugada Syndrome. JACC: Clinical Electrophysiology. 2025. doi:10.1016/j.jacep.2025.01.013
BibTeX
@article{Monaco2025,
author = {Monaco, Cinzia and Cespon-Fernandez, Maria and Pannone, Luigi and Del Monte, Alvise and Della Rocca, Domenico and Gauthey, Anais and Mouram, Sahar and Marcon, Lorenzo and Vetta, Giampaolo and Audiat, Charles and Doundoulakis, Ioannis and Bisignani, Antonio and Miraglia, Vincenzo and Pappaert, Gudrun and Eltsov, Ivan and Bala, Gezim and Sorgente, Antonio and Overeinder, Ingrid and Almorad, Alexandre and Stroker, Erwin and Sarkozy, Andrea and Wellens, Francis and Chierchia, Gian Battista and La Meir, Mark and Sieira, Juan and Brugada, Pedro and de Asmundis, Carlo},
title = {Implantable Cardioverter-Defibrillator Therapy in Brugada Syndrome},
journal = {JACC: Clinical Electrophysiology},
year = {2025},
doi = {10.1016/j.jacep.2025.01.013}
}
EUVIMED